MeritValue

X4 Pharmaceuticals, Inc

XFORdata completeness 100%10 fiscal years on file
The thesis, from the filings

X4 Pharmaceuticals, Inc earns about -171% on invested capital, but has diluted owners by 64% over 5 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own
FigureFY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$01$02$03$2.56M3$35.1M3
Net income−$88.7M4−$93.9M5−$101.2M6−$37.5M6−$79.2M6
Operating cash flow−$70.9M7−$77.1M8−$96.5M9−$130.9M9−$85.6M9
Capital expenditure$615,00010$103,00011$60,00011$326,00011$012
Free cash flow (derived)−$71.5M7−$77.2M8−$96.6M9−$131.2M9−$85.6M9
Total debt$66.4M13$66.1M14$109.6M14$75M15$75M15
Cash & equivalents$81.8M16$121.7M17$99.2M17$55.7M18$217M18
Diluted shares25.7M63.5M5.9M6.7M42.3M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
$44.05
your share of equity
Profit it earned you last year
−$18.73
Free cash flow it threw off
−$20.24
Debt you’d be carrying
$17.73

10 shares is a claim on $44.05 of net worth that earned you −$18.73 and generated −$20.24 of cash last year, against $17.73 of debt.

iii. Is this a good business?
Moat signal · return on invested capital
-171% avg · 5y
FY21 -137%FY22 -385%FY23 -123%FY24 -71%FY25 -141%

It earned an average -171% on invested capital over 5 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →
Management signal · capital allocation
+64% shares · 5y

Share count is up 64% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has risen 13% over the same window.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
DCF · Growth Exit 5Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2021-12-31 · accession 0001628280-23-008745 (RevenueFromContractWithCustomerExcludingAssessedTax)
  2. 10-K · period ending 2022-12-31 · accession 0001628280-25-014805 (RevenueFromContractWithCustomerExcludingAssessedTax)
  3. 10-K · period ending 2023-12-31 · accession 0001501697-26-000018 (RevenueFromContractWithCustomerExcludingAssessedTax)
  4. 10-K · period ending 2021-12-31 · accession 0001628280-24-012578 (NetIncomeLoss)
  5. 10-K · period ending 2022-12-31 · accession 0001628280-25-014805 (NetIncomeLoss)
  6. 10-K · period ending 2023-12-31 · accession 0001501697-26-000018 (NetIncomeLoss)
  7. 10-K · period ending 2021-12-31 · accession 0001628280-24-012578 (NetCashProvidedByUsedInOperatingActivities)
  8. 10-K · period ending 2022-12-31 · accession 0001628280-25-014805 (NetCashProvidedByUsedInOperatingActivities)
  9. 10-K · period ending 2023-12-31 · accession 0001501697-26-000018 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2021-12-31 · accession 0001628280-24-012578 (PaymentsToAcquireProductiveAssets)
  11. 10-K · period ending 2022-12-31 · accession 0001628280-25-014805 (PaymentsToAcquirePropertyPlantAndEquipment)
  12. 10-K · period ending 2025-12-31 · accession 0001501697-26-000018 (PaymentsToAcquireProductiveAssets)
  13. 10-K · period ending 2021-12-31 · accession 0001628280-23-008745 (LongTermDebtNoncurrent)
  14. 10-K · period ending 2022-12-31 · accession 0001628280-24-012578 (LongTermDebtNoncurrent)
  15. 10-K · period ending 2024-12-31 · accession 0001501697-26-000018 (LongTermDebt)
  16. 10-K · period ending 2021-12-31 · accession 0001628280-24-012578 (CashAndCashEquivalentsAtCarryingValue)
  17. 10-K · period ending 2022-12-31 · accession 0001628280-25-014805 (CashAndCashEquivalentsAtCarryingValue)
  18. 10-K · period ending 2024-12-31 · accession 0001501697-26-000018 (CashAndCashEquivalentsAtCarryingValue)